COMBINATION OF HBV IMMUNOTHERAPY WITH SHRNA-MEDIATED PD-1/PDL CHECKPOINT INHIBITION FOR TREATMENT OF CHRONIC HBV

$5,515,484FY2022Defense Health AgencyDOD

Carogen Corp

Investigators